Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

ers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, pr
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... March 05, 2015 Bi-Biomics today ... paraffin and stain additive. The improvement in histological ... binary features present in all daughter cells. , ... chromatin packaging was analyzed at 1000-1600x using light ... chromatin patterning in all daughter cells displayed predominant ...
(Date:3/5/2015)... and TORONTO , March ... APS), a clinical-stage company developing new therapeutics and molecular ... announced that William G. Rice , Ph.D., Chairman, ... upcoming 27th Annual ROTH Conference on Tuesday, March 10 ... Ritz Carlton, Laguna Niguel, CA. ...
(Date:3/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4ld5nw/mature_biotech ) ... Outlook 2015: New Therapy Ventures Pave the Way for ... All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen ... given a positive return and hence increased the interest ... select therapy/niche indication where the high treatment cost justifies ...
(Date:3/5/2015)... Ohio (PRWEB) March 05, 2015 ... Gold Development Partner located in Northeast Ohio, today announced ... e2b teknologies to support its upgrade to the latest ... the largest independent group practice of its kind in ... and large volume of transactions, so efficiency and data ...
Breaking Biology Technology:Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2
... 20 Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), ... products using its proprietary transdermal delivery platform, today announced ... of Transdel, will present a company overview at ... the 4th annual BIOCOM Investor Conference in San Diego, ...
... ATLANTA, Oct. 20 GeoVax Labs, Inc. ... "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for ... infectious agents, today announced that it will move its ... of Emory University to Smyrna, Georgia, a northwest suburb ...
... ... ways to make organic gardening simple, safe and fun. , ... Boston, MA (PRWEB) October 19, 2009 -- It,s no longer ... naturally. As a matter of fact, "as the demand for healthy, fresh fruits and veggies ...
Cached Biology Technology:Transdel Pharmaceuticals to Present at Two Investor Conferences 2Transdel Pharmaceuticals to Present at Two Investor Conferences 3GeoVax Labs, Inc. Moving Operations to Smyrna, Georgia 2GeoVax Labs, Inc. Moving Operations to Smyrna, Georgia 3GeoVax Labs, Inc. Moving Operations to Smyrna, Georgia 4The Growing Demand for Organic Gardening Sprouts New Self Sustaining Innovations 2The Growing Demand for Organic Gardening Sprouts New Self Sustaining Innovations 3
(Date:2/12/2015)... MINNETONKA, Minn. , Feb. 12, 2015 /PRNewswire/ ... technology company specializing in clinical study management systems, ... Partner Program , further distinguishing iMedNet ... for Clinical Research Organizations (CROs) and healthcare consultants.  ... sales support, prospective customer referrals and numerous co-marketing ...
(Date:2/9/2015)... -- Lintec of America recently announced an exclusive license to ... including sheets, yarns and ribbons, developed at the University ... vast industrial resources of the global Lintec Group, headquartered ... America is forming the Nano-Science and Technology Center (NSTC) ... scaling up the manufacturing and commercialization of nano engineered ...
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... website ( http://www.nxt-id.com/ ) as part of its 2015 ... The Company launched its new consumer website for Wocketwallet.com ... , CEO of NXT-ID said, "Our new corporate website ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... far too much salt, and a University of Iowa researcher ... put us in a better mood. UI psychologist Kim ... are deficient in sodium chloride, common table salt, they shy ... substance or pressing a bar that stimulates a pleasant sensation ...
... states the case for protecting the species in ... , recently published by Harvard University Press. ... Bianca Perla, a University of Washington ecologist, and Jennifer ... New York in Stony Brook, shows that animals are ...
... at Children,s National Medical Center have identified ... suffering from sepsis: platelets. The finding, published ... Care Medicine , is the first time doctors have ... this often fatal infection. "Despite many medical ...
Cached Biology News:Study suggests salt might be 'nature's antidepressant' 2Study suggests salt might be 'nature's antidepressant' 3Prairie dog research promotes caring, conservation 2Children's National research links platelets to sepsis-related organ failure 2
... 5'GCCNNNN NGGC3' 3'CGGN NNNNCCG5' Inactivation Conditions: Heat ... phenol treatment followed by ethanol precipitation. Storage ... 0.1mM EDTA, 1.0mM DTT, 0.01% BSA, 50% ... ice. Store at -20C. Unit Definition: One ...
... stainless-steel shaker flask clips, purpose-designed to firmly ... All clips are equipped with a top ... include a bottom retainer spring, and silicon ... expensive glassware. Clips include the required ...
... Red Taq DNA Polymerase is a thermostable ... activity in primer extension and other molecular ... dye which provides easy and quick identification ... and allows confirmation of complete mixing. The ...
... on measurenment of enzyme activity of TRAP ... plate. The procedure includes two incubation steps ... enzyme reaction) separated by a washing ... determination of human enzymaticaly active TRAP 5 ...
Biology Products: